Köchli O R, Sevin B U, Schär G, Haller U
Universitätsfrauenklinik Zürich.
Geburtshilfe Frauenheilkd. 1995 Jan;55(1):7-16. doi: 10.1055/s-2007-1022766.
This presentation gives a summary of the chemosensitivity test results in breast cancer using the ATP-Cell-Viability Assay (ATP-CVA). Other assays and test systems for chemosensitivity testing are also evaluated. Our results with the ATP-CVA in breast cancer cell lines showed that this test system is a reproducible and reliable tool in the screening of new drugs. Our results with drug combinations showed that with the ATP-CVA and the "median effect principle" synergistic and antagonistic effects can be reliably calculated. The application of the ATP- CVA in fresh human breast cancer made it possible to test tumor chemosensitivity in individual patients. We found an evaluability rate of the ATP-CVA of 95% in 116 patients. The chemosensitivity profiles of the tested tumors revealed a big heterogeneity of chemosensitivity results for single and drug combinations. The 22 in vitro/in vivo correlations from patients with metastatic breast cancer treated with at least three cycles of chemotherapy showed a sensitivity of the ATP-CVA of 92% and a specificity of 89%.
These data are encouraging and further investigations on chemosensitivity testing of fresh tumours are currently ongoing in a prospective study at the University of Zurich.
本报告总结了使用ATP细胞活力测定法(ATP - CVA)进行乳腺癌化学敏感性测试的结果。还评估了用于化学敏感性测试的其他测定法和测试系统。我们在乳腺癌细胞系中使用ATP - CVA的结果表明,该测试系统是筛选新药的可重复且可靠的工具。我们对药物组合的研究结果表明,利用ATP - CVA和“中位效应原理”可以可靠地计算协同和拮抗效应。ATP - CVA在新鲜人乳腺癌中的应用使得能够在个体患者中测试肿瘤化学敏感性。我们发现116例患者中ATP - CVA的可评估率为95%。所测试肿瘤的化学敏感性谱显示,单药和药物组合的化学敏感性结果存在很大异质性。对接受至少三个周期化疗的转移性乳腺癌患者进行的22次体外/体内相关性研究表明,ATP - CVA的敏感性为92%,特异性为89%。
这些数据令人鼓舞,苏黎世大学目前正在进行一项前瞻性研究,对新鲜肿瘤的化学敏感性测试进行进一步调查。